Trends in Use of and Survival after Autologous Hematopoietic Cell Transplantation in North America, 1995-2005: Significant Improvement in Survival for Lymphoma and Myeloma during a Period of Increasing Recipient Age

Biology of Blood and Marrow Transplantation

Volumn 19, Issue 7, 2013, Pages 1116-1123

  McCarthy, Philip L ^a   Hahn, Theresa ^a   Hassebroek, Anna ^b   Bredeson, Christopher ^c   Gajewski, James ^d   Hale, Gregory ^e   Isola, Luis ^f   Lazarus, Hillard M ^g   Lee, Stephanie J ^h   LeMaistre, Charles F ⁱ   Loberiza, Fausto ^j   Maziarz, Richard T ^d   Rizzo, J Douglas ^k   Joffe, Steven ^l   Parsons, Susan ^m   Majhail, Navneet S ^b,n  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b CENTER FOR INTERNATIONAL BLOOD AND MARROW TRANSPLANT RESEARCH   (United States)

^c UNIVERSITY OF OTTAWA   (Canada)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^e JOHNS HOPKINS ALL CHILDREN S HOSPITAL   (United States)

^f MOUNT SINAI MEDICAL CENTER   (United States)

^g CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h Fred Hutchinson Cancer Research Center   (United States)

ⁱ Sarah Cannon Cancer Institute   (United States)

^j UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^k CENTER FOR INTERNATIONAL BLOOD AND MARROW TRANSPLANT RESEARCH   (United States)

^l BOSTON CHILDREN S HOSPITAL   (United States)

^m TUFTS MEDICAL CENTER   (United States)

ⁿ NATIONAL MARROW DONOR PROGRAM   (United States)

more..

Author keywords

Autologous transplantation; Lymphoma; Myeloma; Survival; Treatment related mortality

Indexed keywords

BUSULFAN; CARBOPLATIN; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; IFOSFAMIDE; MELPHALAN; THIOTEPA;

ADOLESCENT; ADULT; AGED; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHILD; FEMALE; GRAFT RECIPIENT; HODGKIN DISEASE; HUMAN; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; MYELOMA; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PRESCHOOL CHILD; SCHOOL CHILD; SURVIVAL RATE; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; AGE FACTORS; AGED; CHILD; CHILD, PRESCHOOL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMANS; INFANT; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NORTH AMERICA; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TRANSPLANTATION, AUTOLOGOUS;

EID: 84879336748     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2013.04.027     Document Type: Article

References (19)

1. Pasquini MC, Wang Z. Current use and outcome of hematopoietic stem cell transplantation: CIBMTR summary slides, 2010. Available at: Accessed April 18,2011. http://www.cibmtr.org.
2. Attal M., Harousseau J.L., Stoppa A.M., et al. Intergroupe Français du Myélome. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. NEngl J Med 1996, 335:91-97.
3. Salar A., Sierra J., Gandarillas M., et al. Autologous stem cell transplantation for clinically aggressive non-Hodgkin's lymphoma: the role of preparative regimens. Bone Marrow Transplant 2001, 27:405-412.
4. Farquhar C., Majoribanks J., Lethaby A., Basser R. High-dose chemotherapy for poor prognosis breast cancer: systematic review and meta-analysis. Cancer Treat Rev 2007, 33:325-337.
5. Howard D.H., Kenline C., Lazarus H.M., et al. Abandonment of high-dose chemotherapy/hematopoietic cell transplants for breast cancer following negative trial results. Health Serv Res 2011, 46(6 Pt 1):1762-1777.
6. Ledermann J.A. Lessons learned from a decade of clinical trials of high-dose chemotherapy in ovarian cancer. Int J Gynecol Cancer 2001, 18(Suppl 1):53-58.
7. Bensinger W. Stem-cell transplantation for multiple myeloma in the era of novel drugs. JClin Oncol 2008, 26:480-492.
8. Gisselbrecht C., Glass B., Mounier N., et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. JClin Oncol 2010, 28:4184-4190.
9. Cavo M., Rajkumar S.V., Palumbo A., et al. International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood 2001, 117:6063-6073.
10. National Coverage Determination for Stem Cell Transplantation (110.8.1), version 5, effective August 4, 2010. Available at: Accessed April 19,2011. https://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx%3fNCDId%3d45%26ncdver%3d5%26bc%3dBAAAgAAAAAAA%26.
11. CareFirst BlueCross BlueShield medical policy 7.03.003: high-dose chemotherapy/radiation therapy with allogeneic stem cell support. Last revised May 24, 2010. Available at: Accessed April 19,2011. http://notesnet.carefirst.com/ecommerce/medicalpolicy.nsf/vwwebtablex/71e6ebb6f3d7f1d38525772d004248b8%3fOpenDocument.
12. Cigna medical coverage policy: stem cell transplantation for myelodysplastic syndromes. Effective date October 15, 2010. Available at: Accessed April 19,2011. http://www.cigna.com/customer_care/healthcare_professional/coverage_positions/medical/mm_0187_coveragepositioncriteria_stem_cell_transpl_myelodysplastic_syndr.pdf.
13. Cigna medical coverage policy: stem cell transplantation for multiple myeloma and POEMS. Effective date April 15, 2011. Available at: Accessed April 19,2011. http://www.cigna.com/customer_care/healthcare_professional/coverage_positions/medical/mm_0294_coveragepositioncriteria_stem_cell_transpl_mult_myeloma_poems.pdf.
14. Palumbo A., Cavallo F., Lupo B., et al. Melphalan/prednisone/lenalidomide (MPR) versus high-dose melphalan and autologous transplantation (Mel200) in newly diagnosed multiple myeloma patients: a phase III study [abstract 508]. Haematologica 2011, 96(Suppl 2):214-215.
15. Sonneveld P., Schmidt-Wolf I.G.H., van der Holt B., et al. Bortezomibinduction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/GMMG-HD4 trial. J Clin Oncol 2012, 30:2946-2955.
16. McCarthy P.L., Owzar K., Hofmeister C.C., et al. Lenalidomide after stem-cell transplantation for multiple myeloma. NEngl J Med 2012, 366:1770-1781.
17. Hari P.N., McCarthy P.L. Multiple myeloma: future directions in autologous transplantation and novel agents. Biol Blood Marrow Transplant 2013, 19(Suppl 1):S20-S25.
18. FDA approval for rituximab. Available at: Accessed January 9,2012. http://www.cancer.gov/cancertopics/druginfo/fda-rituximab/print.
19. Characteristics of our aging population. Available at: Accessed September 20,2011. http://transgenerational.org/aging/demographics.htm.